Introduction: Metastatic non-small cell lung cancer (NSCLC) is a recognized risk factor for VTE. Some systemic treatments may increase this risk further. Here, we present the risk of VTE and its prognostic significance for patients treated with chemotherapy (chemo) and the EGFR monoclonal antibody necitumumab (neci) for metastatic NSCLC.
Methods: Four trials of 1st-line treatment for Stage IV NSCLC were analyzed: two randomized phase 3 studies of cisplatin/gemcitabine ±neci in squamous NSCLC (SQUIRE: N = 1079) and cisplatin/pemetrexed ±neci in non-squamous NSCLC (INSPIRE: N = 616); JFCL (N = 161), a randomized phase 2 trial of carboplatin/paclitaxel ±neci in squamous NSCLC; and JFCK (N = 61), a single arm phase 2 trial of cisplatin/gemcitabine +neci in squamous NSCLC. A Cox proportional hazards model with VTE as a time-dependent covariate was used for overall survival (OS) analyses.
Results: Neci + chemo was associated with an increased risk of VTE (Relative Risk [RR]: 1.579; 95% CI: 1.155-2.158). History of VTE (RR: 1.899; 95% CI: 1.142-3.156) and prior cardiac/cardiovascular events (RR: 1.514; 95% CI: 1.102-2.082) were associated with increased risk of VTE. Decreased VTE risk was seen with: male sex (RR: 0.696; 95% CI: 0.502-0.964), eastern European geographic region (RR: 0.387; 95% CI: 0.267-0.562) and squamous cell pathology (RR: 0.653; 95% CI: 0.483-0.883). VTE occurrence showed no association with OS (HR: 1.121; 95% CI: 0.930-1.351).
Conclusion: Our data suggest that certain patient characteristics such as prior history of VTE and non-squamous histology might be associated with an increased risk of on-treatment VTE in NSCLC, although in this study, overall survival was not affected. Further studies to develop measures for identifying high-risk patients are needed to inform treatment decisions as well as VTE management and prophylaxis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2018.05.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Three Decades of Outpatient Plastic Surgery Safety: A Review of 42,720 Consecutive Cases.
Plast Reconstr Surg
December 2024
The Dallas Plastic Surgery Institute, Dallas, TX.
Background: Outpatient plastic surgery offers cost-effective solutions and enhanced privacy but demands careful patient assessment for suitability and vigilant anticipation of adverse events. This study provides recommendations to enhance patient safety in outpatient settings by analyzing over 40,000 consecutive cases spanning across three decades.
Methods: We retrospectively reviewed all consecutive cases completed by board-certified plastic surgeons at an accredited outpatient surgical center between 1995-2023.
A new risk assessment model of venous thromboembolism by considering fuzzy population.
BMC Med Inform Decis Mak
December 2024
Department of Respiration, Peking Union Medical College Hospital, No.1, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Background: Inpatients with high risk of venous thromboembolism (VTE) usually face serious threats to their health and economic conditions. Many studies using machine learning (ML) models to predict VTE risk overlook the impact of class-imbalance problem due to the low incidence rate of VTE, resulting in inferior and unstable model performance, which hinders their ability to replace the Padua model, a widely used linear weighted model in clinic. Our study aims to develop a new VTE risk assessment model suitable for Chinese medical inpatients.
View Article and Find Full Text PDFDevelopment and validation of a nomogram for predicting venous thromboembolism risk in post-surgery patients with cervical cancer.
World J Surg Oncol
December 2024
Chongqing Cancer Multiomics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Objective: Postoperative venous thromboembolism (VTE) is a potentially life-threatening complication. This study aimed to develop a predictive model to identify independent risk factors and estimate the likelihood of VTE in patients undergoing surgery for cervical cancer.
Methods: We conducted a retrospective cohort study involving 1,174 patients who underwent surgery for cervical carcinoma between 2019 and 2022.
The incidence of venous thromboembolism is low when risk stratification-based thromboprophylaxis is used after fast-track hip and knee arthroplasty.
BMC Musculoskelet Disord
December 2024
Department of Surgery, Hospital Nova of Central Finland, Wellbeing Services County of Central Finland, Jyväskylä, University of Eastern Finland, Kuopio, Finland.
Background: The optimal length of thromboprophylaxis after total hip or knee arthroplasty (THA and TKA) is unknown. Fast-track protocols have improved patient care and led to shorter immobilization and length of stay (LOS) after THA and TKA, thereby diminishing venous thromboembolism (VTE) risk. Here, we investigated risk stratification-based thromboprophylaxis after fast-track THA and TKA.
View Article and Find Full Text PDFRisk of Major Adverse Cardiovascular Events and Venous Thromboembolic Events Between Patients With Psoriasis or Psoriatic Arthritis on Tumor Necrosis Factor Inhibitors, Interleukin-17 Inhibitors, Interleukin-12/23 Inhibitors and Interleukin-23 Inhibitors: An Emulated Target Trial Analysis.
J Am Acad Dermatol
December 2024
Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. Electronic address:
Background: The risk of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) in patients with psoriatic disease receiving biologics is not fully understood.
Objective: This study aimed to investigate whether novel biologic therapies (IL-17, IL-12/23, and IL-23 inhibitors) for biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) are associated with differences in the risks of MACE and VTE compared with those with TNF inhibitors.
Methods: An emulated target trial was designed by a nationwide cohort using data from the TriNetX Research Network.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!